key: cord-0430084-k9l7sfbt authors: Suzuki, K.; Ichikawa, T.; Suzuki, S.; Tanino, Y.; Kakinoki, Y. title: C-reactive protein and lactate dehydrogenase are useful biomarkers for predicting the requirement for oxygen therapy in outpatients with coronavirus disease 2019 date: 2021-11-19 journal: nan DOI: 10.1101/2021.11.17.21265553 sha: af0d95c2ee7eb72d803b2d102bf35706971cd263 doc_id: 430084 cord_uid: k9l7sfbt Background It is critical for clinicians seeing outpatients with coronavirus disease 2019 (COVID-19) to identify those who will require oxygen therapy after the hospital visit. Although many studies on biomarkers predicting the study outcomes, including intensive care unit admission, ventilator requirement, or mortality, in hospitalized patients with COVID-19 have been conducted, research on biomarkers predicting the need for oxygen therapy in outpatients is sparse. Methods Patients with COVID-19 who visited Asahikawa City Hospital on an outpatient basis were included in the study. In total, 287 new outpatients visited between April 2021 and September 2021, and 142 underwent blood testing. All blood tests were performed before any treatments for COVID-19 were started. Demographic information, laboratory data, and clinical treatment information were extracted from the electronic medical records. Risk factors associated with oxygen therapy were explored. Results In total, 40 of 142 patients who underwent blood testing required oxygen therapy within 7 days after blood samples were taken, and all other patients recovered without oxygen therapy. C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels were significantly higher in patients who required oxygen therapy, and their cutoffs were 36 mg/L (sensitivity, 0.802; specificity, 0.725) and 267 U/L (sensitivity, 0.713; specificity, 0.750), respectively. Multivariate logistic regression identified age, body mass index, CRP [≥] 36 mg/L, and LDH [≥] 267 U/L as significant risk factors for oxygen therapy. Conclusion This study suggests that elevated CRP and LDH levels are useful biomarkers for predicting the need for oxygen therapy in outpatients with COVID-19. Further confirmatory studies are needed. and 142 underwent blood testing. All blood tests were performed before any treatments for COVID- 23 19 were started. Demographic information, laboratory data, and clinical treatment information were 24 extracted from the electronic medical records. Risk factors associated with oxygen therapy were 25 explored. In total, 40 of 142 patients who underwent blood testing required oxygen therapy within 7 28 days after blood samples were taken, and all other patients recovered without oxygen therapy. C-29 reactive protein (CRP) and lactate dehydrogenase (LDH) levels were significantly higher in patients Conclusion 35 This study suggests that elevated CRP and LDH levels are useful biomarkers for predicting 36 the need for oxygen therapy in outpatients with COVID- 19 . Further confirmatory studies are needed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. predictive of prognosis among outpatients who require admission and oxygen therapy. 60 Therefore, this study analyzed the data of outpatients to identify the biomarkers predictive 61 of the need for oxygen therapy in patients with COVID-19. Additionally, we discussed the optimal 62 cutoffs of the predictive biomarkers. CoV-2) genes and/or antigen quantitation testing. The endpoint of this study was the requirement for oxygen therapy, which was definitely 71 administered to patients with percutaneous oxygen saturation levels of ≤92%. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The opt-out method was used to obtain patient consent in this study. In total, 287 outpatients who visited Asahikawa City Hospital for the first time were eligible 104 for the study. We excluded five patients who were admitted to other hospitals after they visited our 105 hospital because the clinical course data were missing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.17.21265553 doi: medRxiv preprint 4 We divided the patients into two groups according to the need for oxygen therapy. S1 Table 107 presents the characteristics of the 282 outpatients included in the study. Among the included patients, 108 142 received blood tests before any treatment for COVID-19 was started. All blood samples were 109 collected at the outpatient setting. In total, 138 patient samples were collected at the first visit to our 110 hospital's outpatient unit. Four patient samples were collected at the second or third visit. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The ROC curves of WBC, NLR, CRP, AST, and LDH in distinguishing the need for oxygen There was no significant difference in AUC among CRP, LDH, NLR, and AST, whereas that of WBC 146 was significantly lower than those of the other variables (P < 0.05). We selected CRP and LDH for 147 further analysis because they had higher AUCs than the variables and they are routinely used in daily is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint All patients in the oxygen therapy group started therapy within 7 days of blood testing. The Kaplan-Meier distributions revealed a significant difference in the rates of oxygen therapy between 158 low (<35 mg/L and high (≥35 mg/L) CRP levels (log-rank P < 0.001, Fig 3) and between low (<267 159 U/L) and high (≥267 U/L) LDH levels (log-rank P < 0.001*, Fig 4) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 1.02-1.10), 1.15 (1.02-1.29) , 7.83 (2.45-25.1), and 3.9 (1.14-171 13.3), respectively (Fig 5) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.17.21265553 doi: medRxiv preprint with COVID-19 [12] . CRP levels are obviously increased in the presence of acute inflammation, and 186 they might normalize after inflammation subsides [12] . CRP levels in the early stage of COVID-19 187 have been reported to be positively correlated with the presence of lung lesions [13] . During the 188 process of COVID-19 pneumonia, a cytokine response storm can be triggered, which is associated suggesting a CRP cutoff of ≥36 mg/L for identifying outpatients who will require oxygen therapy. LDH is an inflammatory marker that may serve as a common indicator of acute or severe 198 tissue damage [18] . Cytokine-mediated lung tissue damage, which is a primary feature of COVID-199 19, may be responsible for the elevated release of LDH [19] . LDH ≥ 450 U/L on hospitalization was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.17.21265553 doi: medRxiv preprint In conclusion, our data suggest that CRP and LDH are useful biomarkers for predicting the 239 need for oxygen therapy among outpatients with COVID-19. Further clinical studies are necessary to 240 confirm our findings. US cohort D-dimer as a 276 biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in 277 predicting disease outcome in hospitalized patients with COVID-19 Elevated lactate dehydrogenase (LDH) level as an 280 independent risk factor for the severity and mortality of COVID-19 Hematological 283 abnormalities and comorbidities are associated with COVID-19 severity among hospitalized patients: 284 Experience from Bangladesh A new haematocytometric index: 287 Predicting severity and mortality risk value in COVID-19 patients Procalcitonin levels in COVID-19 patients The independent factors associated with oxygen therapy 292 in COVID-19 patients under 65 years old Investigation of the freely available easy-to-use software 'EZR' for medical statistics Update advances on C-reactive protein in COVID-19 and other viral 298 infections C-reactive protein levels in the early stage of COVID-19 Diagnosis of SARS-CoV-2 infection in the setting of the 303 cytokine release syndrome Lactate dehydrogenase 306 and C-reactive protein as predictors of respiratory failure in CoVID-19 patients 310 et al. C-reactive protein as a prognostic indicator in COVID-19 patients The role of C-reactive 313 protein as a prognostic marker in COVID-19 Challenges in routine clinical chemistry analysis: proteins and enzymes Ketones and 319 lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in 320 breast cancer: achieving personalized medicine via Metabolo-Genomics is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.17.21265553 doi: medRxiv preprint